Cited by 168Autoimmune Neurological Disorders and TreatmentsMyasthenia Gravis and ThymomaPeripheral Neuropathies and Disorders

Ganglionic Acetylcholine Receptor Autoantibody: Oncological, Neurological, and Serological Accompaniments

Open access
McKeon, Andrew, Lennon, Vanda A., Lachance, Daniel H., Fealey, Robert D., Pittock, Sean J.·2009·Archives of Neurology

Abstract

OBJECTIVE: To describe the clinical utility of the nicotinic ganglionic acetylcholine receptor (alpha3-AChR) autoantibody as a marker of neurological autoimmunity and cancer. DESIGN: Case-control study. SETTING: Mayo Clinic, Rochester, Minnesota. PATIENTS: A total of 15,000 patients seen at Mayo Clinic (2005-2007) and evaluated on a service basis for paraneoplastic neurological autoimmunity for whom clinical information was obtained retrospectively by medical record review as well as 457 neurologically asymptomatic patients or control subjects of whom 173 were healthy, 245 had lung cancer, and 39 had systemic lupus erythematosus or Sjögren syndrome. OUTCOME MEASURES: Neurological, oncological, and serological associations of alpha3-AChR autoantibody seropositivity. RESULTS: Of 15,000 patients tested on a service basis, 1% were seropositive (median, 0.12 nmol/L; range, 0.03-18.8 nmol/L; normal, < or =0.02 nmol/L), 55% were male, and the median age was 65 years. Cancer was found (new or by history) in 24 of 78 patients evaluated for cancer while at Mayo Clinic (30%); 43% had adenocarcinoma (more patients had breast cancer than prostate, lung, and gastrointestinal cancers; each of the latter groups had about the same number of patients). Of 12 patients with high antibody values (> or =1.00 nmol/L), 83% had pandysautonomia. Of 85 patients with medium antibody values (0.10-0.99 nmol/L), neurological presentations were more diverse and included peripheral neuropathies (36%), dysautonomia (20%, usually limited), and encephalopathy (13%). Of 58 patients with low antibody values (0.03-0.09 nmol/L), 54% had a nonautoimmune neurological disorder or no neurological disorder. Of 245 control patients with lung cancer, 7.8% were seropositive. Only 1 of 212 control patients without cancer (0.5%) was seropositive (P < .001). CONCLUSION: The detection of alpha3-AChR autoantibody aids the diagnosis of neurological autoimmunity and cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/archneurol.2009.78

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Seropositivity for antiganglionic acetylcholine receptor antibodies is the serological hallmark of autoimmune autonomic ganglionopathy.

    “Seropositivity for antiganglionic acetylcholine receptor antibodies is the serological hallmark of autoimmune autonomic ganglionopathy.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [15]Griesmann G Kryzer TJ Lennon VA Rose N Hamilton RG Detrick B Autoantibody profiles of myasthenia gravis and Lambert-Eaton myasthenic syndrome Manual of Clinical Laboratory Immunology Washington, DC ASM Press 2002 1005 1012

Cited by

Sorted by citations

Authors
McKeon, A., Lennon, V. A., Lachance, D. H., Fealey, R. D., & Pittock, S. J.
Affiliations
Mayo Clinic (US)
Venue
Archives of Neurology
Published
2009-06-01
Volume
66
Issue
6
Pages
735-41
ISSN
0003-9942 (ISSN-L)
OpenAlex
W2166446573
Cited by
168
References
20
Citations by year
2026: 7 · 2025: 2 · 2024: 9 · 2023: 6 · 2022: 9 · 2021: 12 · 2020: 9 · 2019: 10 · 2018: 14 · 2017: 9 · 2016: 8 · 2015: 8 · 2014: 8 · 2013: 15 · 2012: 14
FWCI
8.51
Type
journal article
Language
en
Open access
Locations
  • Archives of Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK071209, P01DK068055, R01-DK71209-4, P01-DK-68055)
Topics
  • Health Sciences › Medicine › Neurology › Autoimmune Neurological Disorders and Treatments
  • Health Sciences › Medicine › Neurology › Myasthenia Gravis and Thymoma
  • Health Sciences › Medicine › Neurology › Peripheral Neuropathies and Disorders
Keywords
immunoglobulins, nicotinic acetylcholine receptors, lung cancer, breast cancer, prostate cancer, autonomic dysfunction, peripheral neuropathy, encephalopathy, autoimmune neurological disorders, cancer screening biomarkers, systemic lupus erythematosus, Sjögren's syndrome
MeSH terms
Adenocarcinoma, Aged, Autoantibodies, Autonomic Nervous System Diseases, Encephalitis, Female, Ganglia, Autonomic, Humans, Male, Middle Aged, Neoplasms, Peripheral Nervous System Diseases, Predictive Value of Tests, Receptors, Nicotinic, Retrospective Studies, Biomarkers, Paraneoplastic Syndromes, Nervous System, Primary Dysautonomias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review